KLF2 and COVID-19: These data suggest that pharmacological activation of KLF2 attenuates COVID-19-patient-serum-induced monocyte adhesion to activated endothelial cells, thus providing a proof-of-concept that KLF2 activation has therapeutic potential in limiting endothelial dysfunction in COVID-19.